Overview

A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
PF-03635659 is being developed for the treatment of chronic obstructive pulmonary disease. This is a study to examine the safety, pharmacokinetics and pharmacodynamics of PF-03635659 in patients with Chronic Obstructive Pulmonary Disease (COPD).
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer